Form 4: Calidi Biotherapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
Santidrian Antonio Fernandez, Chief Scientific Officer of Calidi Biotherapeutics, Inc., received 16,000 shares of common stock on August 17, 2026.
Summary
- Grant/award: acquired 16,000 Stock Options (right to buy) on August 17, 2026; holds 16,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Santidrian Antonio Fernandez — Officer (Chief Scientific Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Grant/award | Stock Options (right to buy) | 16,000 | — | — | 16,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Grant/award (16,000 shares) |
Keywords
insider transaction, Form 4, CLDI, Calidi Biotherapeutics, Inc., neutral, Santidrian Antonio Fernandez
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.